Background {#Sec1}
==========

The mission of the World Allergy Organization (WAO) is to advance excellence in clinical care, research, education and training. Clinical practice guidelines are part of this mission. In the last 10 years, WAO produced guidelines on anaphylaxis, allergy prevention, urticaria, allergy training, hereditary angioedema, and molecular diagnosis \[[@CR1]\]. All of these documents aim at deepening the clinician's knowledge, improving the quality of diagnosis and care and reducing inappropriate variation in practice. Application of these guidelines may promote the efficient use of resources, inform and empower patients and support public policies \[[@CR2]\]. However, their introduction into routine daily practice requires a series of educational, social and political steps. If not correctly implemented, the guidelines may fail their objectives and patients may remain exposed to harmful or unnecessary care \[[@CR3]\]. Barriers to guideline implementation may be encountered at different levels \[[@CR4]\]:Individual, as professionals may have difficulty understanding the guidelines' language; they may also introduce personal bias in thinking, balancing benefits and risks, and reaching different conclusions;Motivational, as different factors/barriers may generate different motivational stages in individual professionals;Relating to organizational context, for instance lack of arrangements for continuous learning, and lack of implementation tools;Social, for the interference of existing values and cultures, and for the influence of the opinion of key people;Economic, for insufficient or no reimbursement arrangements, rewards, health care systems or incentives.

To overcome these limitations, a series of educational tools needs to be put into play. In this article, we will evaluate the impact on real life of DRACMA, the GRADE guidelines on diagnosis and treatment of CMA \[[@CR5]\], and their dissemination.

DRACMA's influence on the subsequent literature {#Sec2}
-----------------------------------------------

The original version, published in the World Allergy Organization Journal (WAO Journal), was co-published in Pediatric Allergy and Immunology (PAI) \[[@CR6]\]. In 2011, DRACMA was the most downloaded article from PAI website, the second in 2012 and the third in 2013. The publication in the WAO Journal was the most accessed article in 2011 and 2012. The last available data (up to 2015) still indicate that it ranks in the top ten. Up to August 15, 2017, according the Scopus data, 241 articles cited the two versions. A summary report was published at the end of 2010 \[[@CR7]\]. As for mid-august 2017, it has been cited 109 times thus far, with a 6.57 Field-Weighted Citation Impact. The systematic review proposing the recommendations for Oral Immunotherapy in CMA \[[@CR8]\] has been cited 103 times with a 6.12 Field-Weighted Citation Impact. Thus, DRACMA influenced heavily the subsequent literature on CMA.

DRACMA publications {#Sec3}
-------------------

After ARIA (Allergic Rhinitis and its Impact on Asthma), DRACMA was the second guideline in allergy medicine focused on important patient outcomes, explicitly taking into consideration the patient's values and preferences. It pioneered in applying a systematic approach to collecting the evidence, to separate the concepts of quality of evidence and strength of recommendations, and to transparently report the decision process. The method used for this CMA guideline was highlighted as an example of application of the GRADE methodology in an article cited 58 times \[[@CR9]\]. The application of such principles to the diagnostic tests for CMA warranted a specific report, which has been cited 42 times \[[@CR10]\].

Other articles reported on the global burden of CMA \[[@CR11]\], and on its clinical aspects after the publication of the guideline \[[@CR12]--[@CR14]\].

Guidelines on diagnosis and treatment of food allergy before and after DRACMA {#Sec4}
-----------------------------------------------------------------------------

Prior to DRACMA, a handful of guideline documents for food allergy diagnosis and treatment had been issued by the main scientific societies in America and Europe \[[@CR15]--[@CR17]\]. National position papers and guidelines were available in the Netherlands \[[@CR18]\], Finland \[[@CR19]\], Spain \[[@CR20]\], France \[[@CR21]\], Germany \[[@CR22]\] and Japan \[[@CR23]\]. In general, these guidelines were intended for specific countries and/or for specific geographical areas, so they took stock of local factors of epidemiological, economic, organizational, and social nature. None of these documents used the GRADE methodology.

After 2010, other guidelines in the field of food allergy were proposed. One of them made use of the GRADE methodology in a way similar to DRACMA \[[@CR24]\], another used some form of GRADE \[[@CR25]\], and others were consensus-based documents \[[@CR26]--[@CR30]\]. Some national guidelines were also updated or issued \[[@CR31]--[@CR34]\]. During its 7 years, DRACMA was compared to other food allergy guidelines, illustrating how the values and preferences expressed by the writing committees can modify the recommendations \[[@CR35], [@CR36]\].

The number of citations may reflect the relevance of the different food allergy guidelines: the most cited is the National Institute of Allergy and Infectious Diseases (NIAID) guideline \[[@CR24]\] (392 citations, 5.17 Field-Weighted Citation Impact). DRACMA stands second (241, 6.26), followed by the European Academy of Allergy and Clinical Immunology (EAACI) guidelines \[[@CR25]\] (210, 18.68 Field-Weighted Citation Impact).

Guidelines on diagnosis and treatment of CMA before and after DRACMA {#Sec5}
--------------------------------------------------------------------

By 2010, a few consensus documents provided guidance on the diagnostic and therapeutic aspects of CMA in children \[[@CR37], [@CR38]\]. National position papers and guidelines had been produced in Germany \[[@CR39], [@CR40]\], Italy \[[@CR41]\] and Argentina \[[@CR42]\], reflecting general and local needs and vision.

After the publication, 93 WAO-affiliated national Allergy Societies endorsed the DRACMA guideline. Many of the national meetings of these societies hosted lectures on the topic. DRACMA was presented in many countries, in US, France, Italy, Brazil, Chile, Argentina, Kenya, Egypt, Thailand, and Indonesia, to name a few. In addition, some Allergy Societies outside of WAO, e.g. the Iranian, invited WAO lecturers to present on DRACMA. Following the DRACMA explicit invitations to national implementation, some scientific and regulatory bodies did discuss and actualize it in France \[[@CR43], [@CR44]\], United Kingdom \[[@CR45], [@CR46]\], Middle East \[[@CR47]\], South Africa \[[@CR29], [@CR30]\]. In Mexico, the DRACMA recommendations were incorporated in a large specific guideline \[[@CR48]\].

In other cases, the DRACMA guidelines were directly translated into the national languages, to overcome language barriers. This happened in Italy \[[@CR49]\], in South America with the Spanish translation \[[@CR50]\] and in China \[[@CR51]\]. The Mandarin translation was also discussed to be actualized in the Chinese context \[[@CR52]\].

After these discussions in many countries, DRACMA is now the most cited CMA guideline, followed by the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guideline on cow's-milk protein allergy \[[@CR53]\] (179 citations, 16.56 Field-Weighted Citation Impact) and by the Italian CMA guideline \[[@CR41]\] (51 citations, 4.02 Field-Weighted Citation Impact). The British Society of Allergy and Clinical Immunology (BSACI) guidelines \[[@CR46]\] score 4th (42 citations, 11.57 Field-Weighted Citation Impact).

Economic consequences of DRACMA: Diagnosis {#Sec6}
------------------------------------------

Among the diagnostic approaches proposed during the phases of national adaptation, the British example is of particular interest. In DRACMA, metanalyses of the available literature allowed us to calculate the performance characteristics of common diagnostic methods (skin prick test \[SPT\] and specific IgE determination, at the cut-off values of 3 mm wheal diameter and 0.35 kU~A~/L respectively) vs. the Oral Food Challenge (OFC) reference test. Assessing the clinical history, physicians can determine the diagnostic likelihoods estimating the pre-test probability of CMA. As examples, the pre-test probability will be low in cases of atopic dermatitis or Gastroesophageal Reflux Disease (GERD), average in case of immediate reactions or high in case of anaphylaxis. The DRACMA guidelines recommend -- when possible -- OFC for diagnosing CMA, to avoid the risk of anaphylactic reactions at home in SPT or sIgE false negative cases, unnecessary treatment for false positive cases and inappropriate resource utilization. However, some reasons (availability of appropriate staff, organizational obstacles, resource availability, etc.) may make it difficult to perform an OFC. In settings where OFC is not considered possible or opportune, a pre-test probability estimate may help physicians to reach a highly probable diagnosis using simpler diagnostic tests such as SPTs and/or specific IgE determination. These diagnostic pathways however, allow a small chance of false positive or negative results (Figs. [1](#Fig1){ref-type="fig"} and [2](#Fig2){ref-type="fig"}) \[[@CR13]\].Fig. 1In settings where OFC is not considered a requirement, should in vitro specific IgE determination be used for the diagnosis of CMA in patients suspected of CMA and a positive result of a skin prick test? \[[@CR13]\]Fig. 2In settings where OFC is not considered a requirement, should in vitro specific IgE determination be used for the diagnosis of CMA in patients suspected of CMA and a negative result of a skin prick test? \[[@CR13]\]

The cost of challenge test is reasonable in the majority of cases. In the British context however, challenges were considered \"time-consuming and expensive\" \[[@CR46]\]. For this reason, the BSACI guidelines indicated UK as a setting where OFC is not considered an absolute requirement for the diagnosis of CMA. Taking stock of the DRACMA assessment of the probability of false-positive and false-negative diagnosis in case of high- medium- and low- pretest probability, they recommended the use of history ("typical" vs "non-typical") and SPT as rule-out and diagnostic tests in clinical practice at the primary level. Especially for non IgE-mediated CMA, they underline the role of dietary elimination for the diagnosis. This approach, limiting the role of milk challenge to most doubtful cases, is similar to that proposed by the ESPGHAN \"practical\" guideline, issued in 2012 \[[@CR53]\]. This choice is perhaps cost-effective, but may expose patients to the risk of overdiagnosis. As an example, in the Northern-Irish experience, the application of such strategy resulted in a reduction of prescriptions for symptomatic drugs for GERD, but in a steady increase in prescriptions for special formulas \[[@CR54]\]. Although one may surmise that the diagnostic costs are reduced, the net costs for CMA treatment increased in that community \[[@CR55]\]. This example illustrates how the application of a guideline can influence real life practices and economics.

Economic consequences of DRACMA: Treatment {#Sec7}
------------------------------------------

The DRACMA recommendations proposed an appropriate substitute for different clinical situations. The question on substitute formulas was the following: \"Should amino acid formula, extensively hydrolyzed whey or casein formula, soy formula or rice formula be used in children with IgE-mediated CMA?\".

The answer to this clinical question was structured through the recommendations in the box.

### Box: DRACMA recommendations for CMA management {#Sec8}

***Recommendation 7.1***

*In children with IgE-mediated CMA at high risk of anaphylactic reactions (prior history of anaphylaxis and currently not using extensively hydrolyzed milk formula), we suggest amino acid formula rather than extensively hydrolyzed milk formula (conditional recommendation/very low quality evidence).*

***Underlying values and preferences***

*This recommendation places a relatively high value on avoiding possible anaphylactic reactions and a lower value on avoiding the direct cost of amino acid formula in settings where the cost of amino acid formulas is high.*

***Remarks***

*In controlled settings, a trial feeding with an extensively hydrolyzed milk formula may be appropriate.*

***Recommendation 7.2***

*In children with IgE-mediated CMA at low risk of anaphylactic reactions, (no prior history of anaphylaxis or currently on extensively hydrolyzed milk formula), we suggest extensively hydrolyzed milk formula over amino acid formula (conditional recommendation/very-low quality evidence).*

***Underlying values and preferences***

*This recommendation places a relatively high value on avoiding the direct cost of amino acid formula in settings where the cost of amino acid formula is high. In settings where the cost of amino acid formula is lower, the use of amino acid formula may be equally reasonable.*

***Remarks***

*Extensively hydrolyzed milk formula should be tested in clinical studies before being used. If a new formula is introduced, one should carefully monitor if any adverse reactions develop after first administration.*

In structuring these recommendations, formulas were rated according to a series of parameters. Among them, the price was explicitly indicated as an important factor. The DRACMA panel did a preliminary survey of the mean cost of different types of formulas worldwide (Table [1](#Tab1){ref-type="table"}), from which it was found that feeding an infant with an extensively hydrolyzed formula (eHF) was 2.5 times less expensive than using an amino acid-based formula (AAF). Thus, even if the safety of AAF was higher than eHF, the latter was indicated as the first choice in CMA, except in cases of severe forms CMA with high reactivity (anaphylaxis or eosinophilic esophagitis), where AAF was recommended. Soy formulas (SF) were considered less useful to avoid reactions to soy unless they were more available and negative to skin testing. Extensively hydrolyzed rice formula (eHRF) is probably safer than eHFs, but it was considered at a lower level because it is not present in many countries (including UK).Table 1Mean cost of special formulae worldwide, assessed in October 2009 and used in DRACMA Guidelines, vs. price structure in Italy after the DRACMA implementation \[[@CR5]\]FormulaCost (€/liter)Cost (€ per month)Cost (€/liter)Cost (€ per month)Cow's milk0.9201.5030Cow's milk formula2.0452.044Soy formula51126132eHF6.51356.3139eHRF61357.5165AAF1431812.8281

As every recommendation reports the outcome that was considered most relevant by the expert panel (Box 1), they are flexible and can be subject to different interpretations when the importance of the outcomes in a particular country, or for a particular patient, is different. As the cost of the same formula differs substantially from country to country \[[@CR56]\], the implementation of the recommendations may differ.

In recommendations 7.1 and 7.2, for example, cost makes AAF a second choice when the clinical risk is lower (see "values and preferences"). Elaborating on these considerations, an Italian company decided in 2012 to decrease the cost of their AAF by 30%, so that the cost of AAF dropped from 2.4 to 2 times that of eHF. This did modify the balance of recommendations for a substitute formula. AAF were proposed to children with even less severe forms of CMA, such as CM protein-induced atopic dermatitis.

This example illustrates how DRACMA guidelines did influence the formula market, making appropriate treatments affordable to larger layers of population. Naturally, this is only one of the factors for an appropriate care. In some countries, patients are reimbursed for AAF if "allergy" to eHF has been demonstrated, in others there are no reimbursement policies. This can expose to over-or under-use of special formulas.

Conclusions {#Sec9}
===========

DRACMA promoted a cultural debate among researchers and clinicians, improving the quality of diagnosis and clinical care. The accruing evidence on diagnosis and treatment supports the need for an update. Ideally, the new DRACMA guidelines should include non IgE-mediated CMA, particularly mild-moderate forms of CMA and chronic FPIES, as this part of the discipline has never been subjected to the strictest criteria for EBM, using the GRADE approach. We envisage the updated DRACMA will answer more clinical questions, serving the patients' and the pediatricians' needs in the various contexts.

Not applicable.

Funding {#FPar1}
=======

This review is unfounded.

Availability of data and materials {#FPar2}
==================================

Not applicable.

AF conceived of the review, participated in its design and coordination and helped to draft the manuscript. LD, LT, and AM were the authors of specific parts of the review. All the authors reviewed the manuscript, and lent their reflection and clinical experience. LD did the draft and helped in its finalization. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

Not applicable.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

The authors declare that they have no competing interests.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
